Chronic Hepatitis C
A year is sufficient for most hepatitis patients to show an interferon response
Published in Hepatitis Weekly, July 7th, 2003
"The aim of this study was to examine whether 78 week course of interferon (IFN) retreatment could improve the beneficial effect of IFN in chronic hepatitis C patients compared with 52 week course of IFN retreatment. Inclusion criteria were biopsy-proven chronic hepatitis, serum HCV-RNA level of more than 1 Meq/ml, HCV-genotype 1b, abnormal serum alanine aminotransferase (ALT), and transient negative conversion for HCV-RNA during the initial course of IFN therapy," researchers in Japan reported.
"Forty-one patients were randomly assigned to two groups, receiving total...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-07-07)
More Articles from Hepatitis Weekly
- Hemophilia
HCV-positive hemophiliacs get comprehensive cancer therapy with surveillance - Hepatocellular Carcinoma
Zinc finger transcription factor defines treatment-sensitive liver cancer - Autoimmune Disease
Proper diagnosis and awareness of autoimmune hepatitis compels better survival - Chronic Hepatitis C
Interferon-alpha(2b) induction with ribavirin posts better results against HCV - Hepatology
Obese rats avoid the development of fatty liver with exercise - Blood Safety
Pakistani injection drug users twice as likely to donate blood - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
